Acute-On-Chronic Liver Failure Clinical Trial
Official title:
Sequential Adult Left Lateral Lobe Liver Transplantation for Patients With Early Acute on Chronic Liver Failure: a Single Center, Prospective, Single Arm Study
ACLF is a syndrome characterized by rapid deterioration of liver function in chronic liver disease or undiagnosed chronic liver disease, with a high risk of short-term death. Both CMA and EASL mentioned that there is currently lack of specific drugs and treatment of liver failure. For patients with ACLF who are still graded as 2 or 3 after active medical treatment and/or artificial liver therapy, and the CLIF-C score is less than 64 points, it is recommended to perform liver transplantation as soon as possible within 28 days. Early liver transplantation is crucial for improving the prognosis of ACLF, reducing the risk of postoperative infection, progression from early ACLF to late ACLF, and further improving the 1-year post-transplant survival. The current priority for liver allocation based on MELD-Na can't give priority to liver donor matching to ACLF 1-2. Therefore, expanding the donor liver pool is an urgent need for early treatment of patients with ACLF. France team reviewed the development of APOLT to RAPID technology in liver transplantation for liver cirrhosis. Among them, 9 cases underwent two-step hepatectomy (including 5 cases of orthotopic assisted liver transplantation and 4 cases of RAPID surgery), 8 patients survived until the end of follow-up. Based on the experience of clinical practice, our center proposes and designs a clinical study of sequential adult left lateral lobe liver transplantation (SALT) for the treatment of early ACLF (Grade 1 and 2). On the basis of APOLT and RAPID, the safety and efficacy of sequential adult left lateral lobe liver transplantation were evaluated for the above patients.
Status | Not yet recruiting |
Enrollment | 10 |
Est. completion date | December 30, 2025 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Age 18-70 years old - Diagnosed as acute-on-choronic liver failure according to APASL definition - The severity of chronic and acute liver failure is diagnosed as level 1-2 according to the CANONIC criteria - Signed informed consent and expected cooperation of the patients for treatment and follow up. Exclusion Criteria: - Clinical Frailty Scale score = 7 points - Severe hepatopulmonary syndrome, moderate to severe portal pulmonary hypertension; Surgical procedures with high risk of cardiovascular and pulmonary diseases - Complicated with sepsis, various site infections such as spontaneous peritonitis, biliary tract infections, lung infections, bloodstream infections, urinary system infections, etc., did not improve after 72 hours of anti infection before transplantation; Gram negative bacterial infections resistant to carbapenems within the past 3 months - Grade III-IV hepatic encephalopathy (West Haven classification), shock (with a dose of more than 1ug/Kg/min for demethylated kidney), PaO2/FiO2 value = 150mmHg, renal failure requiring dialysis treatment - Lactic acid greater than 9umol/L - Special types of anatomical variations (such as portal vein III-IV type, etc.) - Severe mental and psychological disorders - Complicated with other diseases such as AIDS or malignant tumors - Any reason why, in the opinion of the investigator, the patient should not participate |
Country | Name | City | State |
---|---|---|---|
China | Renji Hospital, Shanghai Jiao Tong University, School of Medicine | Shanghai |
Lead Sponsor | Collaborator |
---|---|
RenJi Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Survival (OS) | To describe overall survival in patients with ACLF treated with sequential adult left lateral lobe liver transplantation. | 1 year after second stage hepatectomy | |
Secondary | Graft Survival (GS) | To describe graft survival in patients with ACLF treated with sequential adult left lateral lobe liver transplantation | 1 year after second stage hepatectomy | |
Secondary | Postoperative complications | Describe the postoperative complications of sequential adult left lateral lobe liver transplantatiyn surgery | 90 days after liver transplant |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05985863 -
Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04822922 -
Safety of UC-MSC Transfusion for ACLF Patients
|
Phase 2 | |
Recruiting |
NCT04578301 -
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
|
||
Completed |
NCT04983108 -
Utility of Liver and Splenic Stiffness in Predicting Esophageal Varices in Patients With Acute on Chronic Liver Failure
|
||
Withdrawn |
NCT05940610 -
The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05036031 -
Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
|
||
Recruiting |
NCT05019352 -
Cytokine Adsorption in Acute-on-chronic Liver Failure
|
N/A | |
Recruiting |
NCT05421351 -
Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
|
||
Completed |
NCT02321371 -
Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.
|
N/A | |
Completed |
NCT02965560 -
Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure
|
||
Recruiting |
NCT03713489 -
Platelet Transfusion in HBV-related acute-on Chronic Liver Failure
|
N/A | |
Withdrawn |
NCT03629015 -
Safety Study of Stemchymal® in Acute Liver Failure
|
Phase 1 | |
Recruiting |
NCT04621812 -
Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
|
||
Recruiting |
NCT04157465 -
Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients
|
N/A | |
Suspended |
NCT03737448 -
TRimetazidine for acUte on Chronic Liver Failure STudy
|
Phase 1 | |
Recruiting |
NCT06128421 -
Individual Nutrition Support in HBV-ACLF Patients at Nutrition Risk
|
N/A | |
Recruiting |
NCT05700708 -
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
|
||
Completed |
NCT04238416 -
Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF
|
Phase 1 | |
Completed |
NCT03456518 -
Pattern of Acute on Chronic Liver Failure in Patient With HCV Related Chronic Liver Disease
|
||
Recruiting |
NCT03987893 -
PEG3350 in ACLF With Hepatic Encephalopathy
|
Phase 4 |